Emerging therapies with perinatal stem cells and tissues

by Alexey Bersenev on March 26, 2012 · 0 comments

in clinical trials and cases

Post to Twitter

Today, I’d like to introduce a guest post by Frances Verter. Dr. Verter is a Founder and a Director of Parent’s Guide to Cord Blood Foundation.

*********************************************

This is a guest post by Frances Verter

This table is an effort to capture a snapshot of all the current clinical trials that are using stem cells from blood or tissues harvested at birth.

The primary research source for this table was searches of ClinicalTrials.gov between Dec. 2011 and Mar. 2012. I have also relied on Lee Buckler’s posts to his Cell Therapy Blog.

Emerging Therapies with Perinatal Tissues and Stem Cells

Indication Occurance in USA Cell Source Donor Type Stage of Use Trial or Product
Cartilage
Repair
9.6% men >
age 60 and 18% women >
age 60
cord
blood
allogeneic approved by KFDA
Cartistem

Medipost Co. Ltd.
Wound
dressing
Acute burn 450,000 hospital visits per year amnion

amnion
cord tissue

allogeneic

allogeneic

allogeneic

FDA

FDA

Beike trial: 2

BioDfactor

NuCel

NCT01443689

Eye surface repair corneal abrasion incidence 1.57% per year amion allogeneic FDA Prokera
Cerebral Palsy 2 per 1000 full term births cord blood autologous

autologous

autologous

allogeneic

Duke: 2

Georgia: 2

Monterrey:1

SunKwang:2

NCT01147653

NCT01072370

NCT01506258

NCT01528436

Hypoxic Ischemic Encephalopathy 2 per 1000 full term births cord blood autologous clinical trial:
phase 1
NCT00593242
Traumatic Brain Injury 435,000 per year ages 0-14,
#1 cause child death
cord blood autologous clinical trial:
phase 1
NCT01251003
Spinal Cord Injury 12,000 per year cord tissue allogeneic clinical trial:
phase 2
NCT01393977
Hearing loss, sensorineural 1 per 1000 births cord blood autologous clinical trial:
phase 1
NCT01343394
Hypoplastic Left Heart Syndrome 0.2 per 1000 births cord blood autologous clinical trial:
phase 1
NCT01445041
Type 1 Diabetes 1.7 per 1000 ages birth-19 cord blood autologous

autologous

allogeneic

Munchen: 1

U. FL: 2

China: 2

NCT00989547

NCT00873925

NCT01350219

Ischemic Stroke 8.1% adults over age 65 had stroke, #3 cause of adult death
cord blood

cord tissue

cord blood & placental cells

allogeneic


allogeneic



allogeneic
China: 1


Gen Hosp:2



Celgene: 2
NCT01438593


NCT01389453



NCT01310114
Critical Limb Ischemia 2.5 per 1000 people, >80% of them diabetics cord blood allogeneic Clinical trial:
phase 1
NCT01019681
Rheumatoid Arthritis 6 per 1000 people placental cells allogeneic Celgene trial:
phase 2
NCT01261403
Crohn’s Disease 1 per 10,000 people ages 10-19 placental cells allogeneic Celgene trial:
phase 2
NCT01155362

Table copyright Frances Verter, PhD 2012

Related posts:

  1. An update for cord blood clinical trials
  2. Clinical neurotransplantation of fetal tissues – analysis of histological findings

Leave a Comment

Previous post:

Next post: